SHAREHOLDER NOTICE: Goldberg Law PC Announces Securities Class Action Lawsuit against Immunomedics Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--()--Goldberg Law PC ( announces that a class action lawsuit has been filed against Immunomedics Inc. ("Immunomedics" or the "Company") (Nasdaq: IMMU). Investors who purchased or otherwise acquired shares between April 20, 2016 and June 2, 2016 (the “Class Period”), are encouraged to contact the firm in advance of the August 8, 2016 lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at, or by email at

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the complaint, Immunomedics issued false and misleading statements to investors and/or failed to disclose that: the Company’s abstract for antibody-drug IMMU-132 submitted to the American Society of Clinical Oncology (ASCO) for presentation at their 2016 Annual Meeting contained previously disclosed results from a mid-stage study; that Immunomedics misrepresented to ASCO that the abstract contained only updated and previously undisclosed data; and that as a result of the above, ASCO removed the IMMU-132 presentation from the 2016 ASCO Annual Meeting schedule.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.


Goldberg Law PC, Los Angeles
Michael Goldberg, Esq., 800-977-7401
Brian Schall, Esq., 800-977-7401

Goldberg Law PC